Pharmaceutical Executive
IN OUR APRIL 2006 ISSUE, we will explore the results of a reader study—a" pulse check" as we think of it—on the topics of promotional programs, meeting spend, and compliance, cosponsored by Maritz Travel and Pharmaceutical Executive. The study asked industry leaders about their perceptions of their companies' physician meetings in terms of audience, format, and budget, as well as their views on compliance regulations.
IN OUR APRIL 2006 ISSUE, we will explore the results of a reader study—a" pulse check" as we think of it—on the topics of promotional programs, meeting spend, and compliance, cosponsored by Maritz Travel and Pharmaceutical Executive. The study asked industry leaders about their perceptions of their companies' physician meetings in terms of audience, format, and budget, as well as their views on compliance regulations. A total of 61 readers involved in compliance monitoring or management of promotional program budgets within the pharmaceutical industry responded.
Because of the small sample and non-scientific nature of the sampling, the results may not be representative of all Pharm Exec readers. Findings are more qualitative than quantitative, but they help to tell a story even without providing significant statistics. They begin to provide a picture of what your fellow industry executives believe.
Some Highlights Include:
In-person meetings and one-on-one sales calls are the most commonly used meeting formats. Respondents reported that these meeting formats are most effective for conveying product information and gaining strong physician participation.
Many respondents feel that their company is doing only an average job of reaching the right audience and getting a good turnout for their promotional meetings, so there is still much room for improvement.
In general, study respondents feel that pharma companies have taken recent changes in compliance regulations very seriously.
• Two-thirds of respondents agree that the pharma industry is strictly following compliance regulations.
• Respondents report having dedicated compliance departments and legal departments to handle issues related to compliance requests.
On average, companies received 24 compliance requests during the past year; three out of five came from a state, and the rest from federal agencies.
Stay tuned for more info in the April 2006 issue of Pharm Exec.
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
November 22nd 2024Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.